BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"Chertkow H" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Basic Science and Pathogenesis | Borrie MJ; Phillips NA; Best S; Anastasiou-Ventura P; Aydogan T; Beaudoin C; Beuk J; Celotto I; Cole L; Das S; Fogarty J; Fouquet C; Gnassi L; Henri-Bellemare C; Pilon R; Sands J; Stirbu A; Truemner J; Chan S; Tucker A; Gajraj J; Bhangu J; Chertkow H; | 41435411 CONCORDIA |
| 2 | Public Health | Gurve D; Centen AP; Slack PJ; Dang-Vu TT; Belleville S; Anderson ND; Montero-Odasso M; Nygaard HB; Chertkow H; Feldman HH; Brewster PWH; Lim A; | 41434309 PERFORM |
| 3 | Peripheral inflammation in a Canadian cohort of neurodegenerative conditions: Occurrence, determinants, and impact | Seixas-Lima B; Rosa-Neto P; Phillips NA; Borrie M; Roncero CT; Lahiri D; Dori D; Eintracht S; Chertkow H; | 41358624 PSYCHOLOGY |
| 4 | Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research | Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Collins DL; Dadar M; DeMarco ML; Ducharme S; Duchesne S; Einstein G; Fisk JD; Gawryluk JR; Grossman L; Ismail Z; Itzhak I; Joshi M; Harrison A; Kroger E; Kumar S; Laforce R; Lanctot KL; Lau M; Lee L; Masellis M; Massoud F; Mitchell SB; Montero-Odasso M; Myers Barnett K; Nygaard HB; Pasternak SH; Peters J; Rajah MN; Robillard JM; Rockwood K; Rosa-Neto P; Seitz DP; Soucy JP; Trenaman SC; Wellington CL; Zadem A; Chertkow H; | 39893139 CONCORDIA |
| 5 | Basic Science and Pathogenesis | Lima BS; Rosa-Neto P; Phillips N; Borrie M; Roncero CT; Lahiri D; Dori D; Chertkow H; | 39751468 CONCORDIA |
| 6 | Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA) | Chertkow H; Phillips N; Rockwood K; Anderson N; Andrew MK; Bartha R; Beaudoin C; Bélanger N; Bellec P; Belleville S; Bergman H; Best S; Bethell J; Bherer L; Black S; Borrie M; Camicioli R; Carrier J; Cashman N; Chan S; Crowshoe L; Cuello C; Cynader M; Dang-Vu T; Das S; Dixon RA; Ducharme S; Einstein G; Evans AC; Fahnestock M; Feldman H; Ferland G; Finger E; Fisk JD; Fogarty J; Fon E; Gan-Or Z; Gauthier S; Greenwood C; Henri-Bellemare C; Herrmann N; Hogan DB; Hsiung R; Itzhak I; Jacklin K; Lanctôt K; Lim A; MacKenzie I; Masellis M; Maxwell C; McAiney C; McGilton K; McLaurin J; Mihailidis A; Mohades Z; Montero-Odasso M; Morgan D; Naglie G; Nygaard H; O' Connell M; Petersen R; Pilon R; Rajah MN; Rapoport M; Roach P; Robillard JM; Rogaeva E; Rosa-Neto P; Rylett J; Sadavoy J; St George-Hyslop P; Seitz D; Smith E; Stefanovic B; Vedel I; Walker JD; Wellington C; Whitehead V; Wittich W; | 39636028 HKAP |
| 7 | A person with frontotemporal dementia shows increased metabolic rate across multiple brain regions after a series of tDCS sessions | Roncero C; Nikelski J; Soucy JP; Lahiri D; Seixas-Lima B; Chertkow H; | 37182684 PERFORM |
| 8 | Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab | Chertkow H; Rockwood K; Hogan DB; Phillips N; Montero-Odasso M; Amanullah S; Black S; Bocti C; Borrie M; Feldman H; Freedman M; Hsiung R; Kirk A; Masellis M; Nygaard H; Rajji T; Verret L; | 34912492 PSYCHOLOGY |
| 9 | Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. | Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants | 32725777 PERFORM |
| 10 | Clinical judgement is paramount when performing cognitive screening during COVID-19. | Phillips NA, Andrews M, Chertkow H, Pichora-Fuller MK, Rockwood K, Wittich W | 32396983 PSYCHOLOGY |
| 11 | Special issues on using the MoCA for remote assessment during COVID-19 2. | Phillips NA, Chertkow H, Pichora-Fuller MK, Wittich W | 32253754 PSYCHOLOGY |
| 12 | The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. | Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K, Tierney MC, Andrew M, Hsiung GR, Camicioli R, Smith EE, Fogarty J, Lindsay J, Best S, Evans A, Das S, Mohaddes Z, Pilon R, Poirier J, Phillips NA, MacNamara E, Dixon RA, Duchesne S, MacKenzie I, Rylett RJ | 31309917 PSYCHOLOGY |
| 13 | Functional and anatomical memory indices in patients with or at risk for Alzheimer's disease. | Phillips NA, Chertkow H, Leblanc MM, Pim H, Murtha S | 15012840 PSYCHOLOGY |
| Title: | Basic Science and Pathogenesis | ||||
| Authors: | Borrie MJ, Phillips NA, Best S, Anastasiou-Ventura P, Aydogan T, Beaudoin C, Beuk J, Celotto I, Cole L, Das S, Fogarty J, Fouquet C, Gnassi L, Henri-Bellemare C, Pilon R, Sands J, Stirbu A, Truemner J, Chan S, Tucker A, Gajraj J, Bhangu J, Chertkow H | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/41435411/ | ||||
| DOI: | 10.1002/alz70855_100224 | ||||
| Publication: | Alzheimer s & dementia : the journal of the Alzheimer s Association | ||||
| Keywords: | |||||
| PMID: | 41435411 | Category: | Date Added: | 2025-12-23 | |
| Dept Affiliation: |
CONCORDIA
1 Division of Geriatric Medicine, Western University, London, ON, Canada. 2 Lawson Research Institute, London, ON, Canada. 3 St. Joseph's Health Care London, London, ON, Canada. 4 Parkwood Institute, London, ON, Canada. 5 Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. 6 Concordia University, Montréal, QC, Canada. 7 Lady Davis Research Institute, Montréal, QC, Canada. 8 Lady Davis Institute, Montréal, QC, Canada. 9 McGill Centre for Integrative Neuroscience, Montréal, QC, Canada. 10 Baycrest Health Sciences, Toronto, ON, Canada. 11 Institut universitaire de gériatrie de Montréal, Montréal, QC, Canada. 12 Lady Davis Resesarch Institute, Montréal, QC, Canada. 13 Lady Davis Research Insitute, Montréal, QC, Canada. 14 University of Toronto, Toronto, ON, Canada. 15 Western University, London, ON, Canada. 16 Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada. 17 Kimel Family Centre for Brain Health and Wellness and Anne & Allan Bank Centre for Clinical Research Trials, Baycrest Health Sciences, Toronto, ON, Canada. 18 Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada. 19 Baycrest and Rotman Research Institute, Toronto, ON, Canada. 20 McGill University, Montreal, QC, Canada. |
||||
Description: |
Background: The Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND) used wide inclusion criteria recruiting participants across the spectrum from normal cognition to cognitive impairment to all types of clinical dementia, including mixed dementia. 1173 participants comprising 11 diagnostic cohorts, completed screening, clinical, neuropsychology, sensory and motor assessments, magnetic resonance imaging (MRI) and provided biomarker bio-samples. Method: Recruitment was from advertising and specialty clinics for neurocognitive disorders and/or memory impairment. Robust data monitoring and cleaning occurred on the baseline and Time 2 data. Genetic, MRI, Cerebrospinal Fluid (CSF) and the majority of blood biomarkers analyses have been completed. Result: Data releases uploaded to the Longitudinal Online Research and Imaging System (LORIS) include alpha numeric baseline data, neuroimaging analyses, CSF, genetic and blood biomarkers. 40 autopsies have been completed. 119 data access requests have been submitted to the Data Access Subcommittee. All returning participants will repeat Time 3 extensive clinical and neuropsychology assessments, MRI and provide bio-samples. Phase III new recruitment will include 400 diverse participants, with up to Grade 12 education, who are not cognitively impaired, or who have cognitive impairment, but not dementia. The balance of each cohort for sex/gender will be a consideration. Conclusion: COMPASS-ND fills a knowledge gap by recruiting participants representing the full spectrum of neurodegeneration. This distinguishes COMPASS-ND from other large-scale studies. Challenges and strategies for engagement and research site level funding will be discussed. Data are available to registered researchers and trainees in Canada and around the world through data access requests. |
